報價延遲最少15分鐘:2025/05/10 04:37 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
30.13 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
2.09/1.46
|
|
企業價值
5.08B
|
| 資產負債 |
|
每股賬面淨值
9.17
|
| 現金流量 |
|
現金流量率
0.10
|
| 損益表 |
|
收益
1.56B
|
|
每股收益
9.65
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/05/10 04:37 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world. |